Johnson & Johnson's Erleada plus ADT cuts prostate cancer recurrence or death risk 62% versus surgery alone in study

By Public Technologies
  • Johnson & Johnson announced Phase 3 PROTEUS substudy results showing perioperative Erleada with hormone therapy reduced recurrence or death versus surgery alone.
  • The regimen also delayed subsequent treatment and showed a numerical improvement in survival without metastasis in high-risk localized or locally advanced prostate cancer.
  • Results were presented at the European Society for Medical Oncology Congress 2026, building on primary findings presented at ASCO 2026.
  • Severe adverse events were more frequent with the regimen, which remains unapproved for this use; overall survival follow-up continues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610240854PR_NEWS_USPR_____NY80016) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.